Moderna has been locked in a legal battle with Pfizer-BioNTech over their COVID shot Comirnaty after suing them in 2022 for allegedly copying its mRNA technology
said on Friday the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer
Pfizer and BioNTech have countersued, alleging that Moderna’s patent is invalid, after the companies’ rival vaccines generated billions in revenues during the pandemic.“Irrespective of the outcome of this legal matter, we will continue to manufacture and supply the Pfizer-BioNTech COVID-19 vaccine,” Pfizer said in a statement to Reuters.
The oral decision was handed down on Thursday, the Financial Times, which was the first to report on the matter, said. The report added a written decision is expected to be published in the coming months.
Canada News Breaking News Video Canadian Breaking News Breaking News Globe And Mail Breaking News Globe And Mail Canada News Photos World News Local News National News Us News Foreign News Sports News Arts News Life News Lifestyle Canada Traffic Canada Weather Trudeau Government Federal Government Canada Sports Canada Sports News Politics Politics News Political News Political Opinion Environment Economy Technology Education Travel Canada Alberta Bc British Columbia Manitoba Ontario Quebec Nova Scotia Pei New Brunswick Newfoundland And Labrador Nunavut Northwest Territories Yukon Globe And Mail
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna wins patent case in Europe against Pfizer, BioNTech over COVID shotPfizer said it was disappointed and would consider all legal options and may appeal the decision
Read more »
Moderna CEO on the changing COVID market: Pandemic to endemicShares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter...
Read more »
Moderna’s mRNA Dreams Meet Reality With First Post-Covid ShotThe biotech’s lackluster new RSV vaccine undercuts the promise of mRNA to revolutionize health care.
Read more »
Moderna Beats Quarterly Estimates as Cost-Cutting Pares LossesModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech giant’s cost-cutting helped offset a steep decline in its Covid business.
Read more »
Moderna quarterly sales beat expectations but plummet from previous yearExplore stories from Atlantic Canada.
Read more »
Novo Nordisk slides while Moderna pops: Tale of two pharma stocksPharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall...
Read more »